Summary of Purpose
To obtain a better understanding on the comparative effectiveness of rivaroxaban versus VKA(Vitamin K antagonist) for stroke prevention in patients with NVAF(non-valvular atrial fibrillation) in a real-life settingRead More →
The following dates are available for this trial. Trial information last updated on 4 April 2017.
|12 Feb 2016||19 Feb 2016||1 Mar 2016||1 Mar 2016||1 Apr 2017||Unavailable|
|Start Date||First Received||1st Completion||Completion||Verification||Results|
- Observation: Cohort
- Perspective: Retrospective
- Sampling: Non-Probability Sample